Serum Neudesin Levels in Patients with Congenital Hypothyroidism
Objective: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital h...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayincilik
2025-09-01
|
| Series: | JCRPE |
| Subjects: | |
| Online Access: | https://www.jcrpe.org/articles/serum-neudesin-levels-in-patients-with-congenital-hypothyroidism/doi/jcrpe.galenos.2025.2024-1-14 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849225016580767744 |
|---|---|
| author | Semra Bahar İlker Tolga Özgen Yaşar Cesur Caner Yıldız Ömer Faruk Özer Emel Hatun Aytaç Kaplan Zümrüt Kocabey Sütçü |
| author_facet | Semra Bahar İlker Tolga Özgen Yaşar Cesur Caner Yıldız Ömer Faruk Özer Emel Hatun Aytaç Kaplan Zümrüt Kocabey Sütçü |
| author_sort | Semra Bahar |
| collection | DOAJ |
| description | Objective: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital hypothyroidism (CH) without treatment. Given the role of neudesin in brain development and its contribution to the survival of mature neurons, the relationship between neudesin and thyroid hormone was evaluated in babies diagnosed with CH.
Methods: Babies aged between 2-4 weeks and diagnosed with CH and healthy controls of similar age were included. All patients were evaluated for thyroid hormones and plasma neudesin levels. The basal neudesin levels between the patient and control groups and the patients’ neudesin levels before and after l-thyroxine treatment were compared.
Results: Fifty-two babies [32 with CH, 14 (44%) female, aged 19±7 days and 20 healthy controls, 7 (35%) female, aged 22±8 days] were included. There was no significant difference in baseline neudesin between the CH and control groups (6.77±6.41 vs. 7.93±7.04 ng/mL, respectively; p=0.552). However, neudesin levels increased significantly following one month of therapy in the CH group [median: 3.93 (minimum: 0.31, maximum: 30.06) vs. median: 6.15 (minimum: 2.17, maximum: 70.05) ng/mL, p=0.019].
Conclusion: Although there was no difference in baseline neudesin levels between the patient and control groups, neudesin levels increased after short-term treatment. Larger prospective studies are needed to understand the pathophysiological role of neudesin in untreated and treated early CH. |
| format | Article |
| id | doaj-art-3de2db57d6f248f9ab3211022483a784 |
| institution | Kabale University |
| issn | 1308-5727 1308-5735 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Galenos Yayincilik |
| record_format | Article |
| series | JCRPE |
| spelling | doaj-art-3de2db57d6f248f9ab3211022483a7842025-08-25T06:11:27ZengGalenos YayincilikJCRPE1308-57271308-57352025-09-0117326326810.4274/jcrpe.galenos.2025.2024-1-14Serum Neudesin Levels in Patients with Congenital HypothyroidismSemra Bahar0https://orcid.org/0000-0002-7113-9646İlker Tolga Özgen1https://orcid.org/0000-0001-6592-9652Yaşar Cesur2https://orcid.org/0000-0002-8972-6494Caner Yıldız3https://orcid.org/0000-0003-2047-7271Ömer Faruk Özer4https://orcid.org/0000-0002-9034-4805Emel Hatun Aytaç Kaplan5https://orcid.org/0000-0002-8385-4049Zümrüt Kocabey Sütçü6https://orcid.org/0000-0001-7335-1272Bezmialem Vakıf University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İstanbul, TürkiyeBiruni University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İstanbul, TürkiyeBezmialem Vakıf University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İstanbul, TürkiyeBezmialem Vakıf University Faculty of Medicine, Department of Biochemistry, İstanbul, TürkiyeBiruni University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İstanbul, TürkiyeUniversity of Health Sciences Türkiye, Başakşehir Çam and Sakura City Hospital, Clinic of Pediatrics, Division of Pediatric Endocrinology, İstanbul, TürkiyeUniversity of Health Sciences Türkiye, Başakşehir Çam and Sakura City Hospital, Clinic of Pediatrics, Division of Pediatric Endocrinology, İstanbul, TürkiyeObjective: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital hypothyroidism (CH) without treatment. Given the role of neudesin in brain development and its contribution to the survival of mature neurons, the relationship between neudesin and thyroid hormone was evaluated in babies diagnosed with CH. Methods: Babies aged between 2-4 weeks and diagnosed with CH and healthy controls of similar age were included. All patients were evaluated for thyroid hormones and plasma neudesin levels. The basal neudesin levels between the patient and control groups and the patients’ neudesin levels before and after l-thyroxine treatment were compared. Results: Fifty-two babies [32 with CH, 14 (44%) female, aged 19±7 days and 20 healthy controls, 7 (35%) female, aged 22±8 days] were included. There was no significant difference in baseline neudesin between the CH and control groups (6.77±6.41 vs. 7.93±7.04 ng/mL, respectively; p=0.552). However, neudesin levels increased significantly following one month of therapy in the CH group [median: 3.93 (minimum: 0.31, maximum: 30.06) vs. median: 6.15 (minimum: 2.17, maximum: 70.05) ng/mL, p=0.019]. Conclusion: Although there was no difference in baseline neudesin levels between the patient and control groups, neudesin levels increased after short-term treatment. Larger prospective studies are needed to understand the pathophysiological role of neudesin in untreated and treated early CH.https://www.jcrpe.org/articles/serum-neudesin-levels-in-patients-with-congenital-hypothyroidism/doi/jcrpe.galenos.2025.2024-1-14congenital hypothyroidismneudesinlevothyroxine sodium |
| spellingShingle | Semra Bahar İlker Tolga Özgen Yaşar Cesur Caner Yıldız Ömer Faruk Özer Emel Hatun Aytaç Kaplan Zümrüt Kocabey Sütçü Serum Neudesin Levels in Patients with Congenital Hypothyroidism JCRPE congenital hypothyroidism neudesin levothyroxine sodium |
| title | Serum Neudesin Levels in Patients with Congenital Hypothyroidism |
| title_full | Serum Neudesin Levels in Patients with Congenital Hypothyroidism |
| title_fullStr | Serum Neudesin Levels in Patients with Congenital Hypothyroidism |
| title_full_unstemmed | Serum Neudesin Levels in Patients with Congenital Hypothyroidism |
| title_short | Serum Neudesin Levels in Patients with Congenital Hypothyroidism |
| title_sort | serum neudesin levels in patients with congenital hypothyroidism |
| topic | congenital hypothyroidism neudesin levothyroxine sodium |
| url | https://www.jcrpe.org/articles/serum-neudesin-levels-in-patients-with-congenital-hypothyroidism/doi/jcrpe.galenos.2025.2024-1-14 |
| work_keys_str_mv | AT semrabahar serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT ilkertolgaozgen serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT yasarcesur serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT caneryıldız serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT omerfarukozer serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT emelhatunaytackaplan serumneudesinlevelsinpatientswithcongenitalhypothyroidism AT zumrutkocabeysutcu serumneudesinlevelsinpatientswithcongenitalhypothyroidism |